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Abstract 
Background 
Foetal antigen 2 (FA-2), first isolated in the amniotic fluid, was shown to be the circulating form of 
the aminopropeptide of the alpha 1 chain of procollagen type I. Serum concentrations of FA-2 
appeared to be elevated in a number of disorders of bone metabolism. This paper is the first report of 
its role as a marker of bone metabolism in metastatic breast cancer. 
Methods 
Serum FA-2 concentrations were measured by radioimmunoassay in 153 women with different 
stages of breast cancer and in 34 normal controls. 
Results 
Serum FA-2 was significantly elevated in women with bony metastases (p < 0.015). Its levels were 
not significantly different among women with non-bony metastases, with non-metastatic disease, as 
well as among normal controls. 
Conclusions 
FA-2 is a promising blood marker of bone metabolism. Further studies to delineate its role in the 
diagnosis and management of bony metastases from breast cancer are required. 
Background 
Foetal antigen 2 (FA-2) was first isolated in the amniotic fluid [1] and subsequent structural 
characterisation showed that it was the circulating form of the aminopropeptide of the alpha 1 chain 
of procollagen type I [2]. As will be discussed later, serum concentrations of FA-2 appeared to be 
elevated in a number of disorders with altered bone metabolism. The bone is the commonest site of 
involvement in metastatic breast cancer. Bone metabolism, including formation and resorption, is 
influenced by the disease process, by anti-cancer therapies (cytotoxic or endocrine therapy) and by 
the recently popularised use of bisphosphonates. A circulating marker which can better reflect the 
process of bone metabolism is needed in the management of women with bony metastases from 
breast cancer, in addition to currently available markers of tumour load (eg MUC1 mucin measured 
as cancer antigen 15.3 (CA15.3), carcinoembryonic antigen (CEA)). FA-2 seems to be a promising 
marker of such kind. This paper analyses the serum levels of FA-2 in different stages of breast cancer 
and examines its role as a marker of bone metabolism in metastatic breast cancer. 
Methods 
Patients 
Blood samples were obtained with informed consents from the following four groups of women seen 
in the Nottingham Breast Unit: 
1. Normal - This included women from two sources. The first group were women attending the 
Screening Assessment Clinic according to the UK National Health Service Breast Screening 
Programme and were proven after assessment (clinical, radiological and/or histological) to have no 
malignancy in the breast. The second group of women attended the Benign Lumps Clinic and they 
had been proven by investigations (including imaging and histology) to have either benign lump(s) 
or no abnormality in the breast. 
2. Women with primary breast cancer (PBC) - All had tumour < 5 cm and blood samples were taken 
at the preoperative assessment clinic prior to surgery. 
3. Women with locally advanced primary breast cancer (LAPC) - These women had LAPC as 
defined by having tumour > 5 cm and/or other features of locally advanced disease (eg inflammatory 
cancer, fixation to chest wall, ulcerating tumour) without any evidence of distant metastases and 
attended the LAPC Clinic. Blood samples were taken when the tumour was still in situ. 
4. Women with advanced breast cancer (ABC) - These were women attending the ABC Clinic and 
all had distant metastases. 
Preparation of Serum Samples 
Blood obtained by venesection was collected in plain tubes, allowed to stand for at least 30 minutes 
and then centrifuged at 2,500 revolutions per minute for 20 minutes. Serum was pipetted into 1-ml 
aliquots and stored in the freezer at -20°C. 
FA-2 Assays 
The serum samples were transported at -20°C to the Williamson Laboratory at St Bartholomew's 
Hospital. FA-2 radioimmunoassays were carried out as previously described [3]. The assays were 
performed in a blind manner with aliquots tagged with a sample number without any clinical 
information. 
Statistical Methods 
Statistical analysis was carried out using the standardised biomedical computer programme SPSS for 
Windows (SPSS UK Ltd). The ANOVA test was used for multiple group comparison of the mean 
values. Statistically significant difference was defined by p < 0.05. 
The authors confirm that approval has been obtained from Local Research Ethics Committee to 
conduct this study on blood markers in breast cancer. 
Results 
The mean values of serum FA-2 levels in all four groups of women were summarised in Table 1. 
There was no difference in FA-2 levels among normal women and women with breast cancer which 
was still confined to the breast (ie PBC and LAPC) (Tables 1 and 2). Nevertheless, when all stages of 
cancer were taken into consideration, FA-2 levels appeared to be significantly elevated in cancer 
patients when compared to normal women and this was due to marked elevation in women with 
metastatic breast cancer (Table 2). Women with metastatic disease had a much higher value of FA-2 
than those without (Table 3) and this was due to the significant elevation of FA-2 in women with 
bony metastases (Figure 1). 
Figure 1. Comparison of FA-2 levels between bone and non-bone metastases. 
Table 1. Mean Values of FA-2 for All Women 
Table 2. Comparison of FA-2 Levels between Different Groups 
Table 3. Comparison of FA-2 Levels between Metastatic and Non-Metastatic Cancers 
In conclusion, the results suggested that FA-2 was significantly elevated only in the subgroup of 
women with bony metastases. 
Discussion 
Blood tumour markers in breast cancer have been known for decades. In contrast to markers in the 
primary tumour tissue, blood tumour markers reflect a dynamic situation and their measurements can 
be repeated as required. The use of blood tumour markers is most established in the diagnosis and 
monitoring of symptomatic metastatic disease. In the diagnosis of metastatic breast cancer, CA15.3 
assay has been shown to be superior with CEA being the next most clinically useful marker [4]. The 
sensitivity can be further increased when a panel of three markers ie CA15.3, CEA and ESR are used 
[5-8]. While the usefulness of blood tumour markers is well established in advanced breast cancer, 
active research, both clinical and laboratory, is ongoing to refine the measurements of existing 
markers, to explore newer markers and to develop better marker assays, aiming to optimise their use 
in advanced disease as well as to exploit their use in screening and diagnosis of early primary breast 
cancer. 
Markers of bone metabolism are among the new markers which are being investigated. Traditional 
markers of bone metabolism include serum alkaline phosphatase, serum and urinary calcium, urinary 
hydroxproline etc. Markers of collagen synthesis have been evaluated as bone markers for metastatic 
bone disease due to breast cancer. The most abundant protein in bone is type I collagen. During its 
formation two extension peptides from the procollagen molecule, carboxy- and aminoterminal 
propeptides (PICP and PINP) are released into the circulation and they are markers of bone 
formation. Type I collagen carboxyterminal telopeptide (ICTP) is formed during bone collagen 
breakdown and is again liberated into the circulation. Its level in the serum therefore reflects bone 
resorption. ICTP has a high specificity though relatively low sensitivity and is the best bone 
metabolism marker evaluated [9,10]. Further studies to evaluate the cost-effectiveness of measuring 
these markers and to explore newer markers of bone metabolism are required [11]. 
After its isolation from the amniotic fluid, FA-2 was found elevated in serum of patients with renal 
osteodystrophy [12] and with primary hyperparathyroidism [13]. Patients with the latter had FA-2 
levels dropped significantly after surgical removal of the parathyroid glands [13]. All these have 
suggested FA-2 as a possible marker to evaluate bone metabolism. Evidence of FA-2 synthesis by 
foetal osteoblasts shown using immunohistochemical staining techniques has substantiated this 
potential role [14]. 
The present study is the first report of the measurement of serum FA-2 in different stages of breast 
cancer. It showed that serum FA-2 was elevated distinctly in women with bony metastases. Its levels 
were significantly lower in women without metastases including normal controls. The fact that the 
mean value in women with metastases was significantly higher that in women without could entirely 
be explained by the inclusion of women with bony metastases in the former group. The mean value 
in women with non-bony metastases was virtually similar to that of those without metastases. In 
essence serum FA-2 has been found to be significantly elevated only in the subgroup of women with 
bony metastases. These preliminary data point out that FA-2 is a potential helpful blood marker for 
bony metastases from breast cancer. It would therefore appear that serum FA-2 measurement may be 
useful in the diagnosis of bony metastases. Whether it will be shown to be superior to existing 
markers and/or radiological methods remains to be elucidated. 
The other role of tumour marker measurement is in the monitoring of therapy. In the present era 
when the use of bisphosphonates has been popularised in the management of bone metastases for 
breast cancer, markers of bone metabolism might provide a measurement of the effect of sclerosis on 
the bone while conventional blood markers such as CA15.3 and CEA reflect the efficacy of anti-
cancer therapy on tumour mass. In these ways new markers have a complementary rather than an 
exclusive role in the diagnosis and monitoring of breast cancer [11]. 
Given the preliminary results from this observational study which has its statistical limitations due to 
its small size, further studies are therefore required to define in details the exact value of serum FA-2 
measurement in bony metastases from breast cancer. Comparison with conventional markers of 
tumour mass (eg CA15.3, CEA) and known novel markers of bone metabolism (eg PICP, PINP, 
ICTP) (both in the diagnosis and in the monitoring of response to systemic therapy), and 
identification of the pattern of changes of serum FA-2 levels in relation to bisphosphonate therapy 
and events such as hypercalcaemia are areas that need to be explored before the use of FA-2 could be 
incorporated into daily clinical practice. 
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